CTIC — CTI Biopharma Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.20bn
- $1.26bn
- $53.95m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 445.59 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 15.82 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -122.44% | ||
| Return on Equity | n/a | ||
| Operating Margin | -71.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 26.29 | 3.35 | n/a | n/a | 53.95 | 117.88 | 236.46 | 16.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CTI BioPharma Corp. is a commercial biopharmaceutical company. It is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, mutant JAK2 form, IRAK1, ACVR1 (ALK2) and FLT3 for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3, ACVR1 and CSF1R.
Directors
- Laurent Fischer NEC (57)
- Adam Craig PRE (55)
- David Kirske CFO (66)
- Bruce Seeley COO (57)
- Diane Parks DRC (69)
- Michael Metzger NID (50)
- David Parkinson NID (70)
- Matthew Perry NID (48)
- Reed Tuckson NID (70)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- December 14th, 2017
- Public Since
- March 21st, 1997
- No. of Shareholders
- 106
- No. of Employees
- 128
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 131,880,176
- Address
- 3101 Western Avenue, Suite 800, SEATTLE, 98121
- Web
- https://www.ctibiopharma.com/
- Phone
- +1 2062827100
- Auditors
- Ernst & Young LLP
Upcoming Events for CTIC
Q3 2023 CTI Biopharma Corp Earnings Release
Similar to CTIC
180 Life Sciences
NASDAQ Capital Market
9 Meters Biopharma
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Aceragen
NASDAQ Capital Market
FAQ
What is the CTI Biopharma share price?
As of Today at 01:05 UTC, shares in CTI Biopharma are trading at $9.09. This share price information is delayed by 15 minutes.
How has the CTI Biopharma share price performed this year?
Shares in CTI Biopharma last closed at $9.09 and the price had moved by +52.52% over the past 365 days. In terms of relative price strength the CTI Biopharma share price has outperformed the S&P500 Index by +33.12% over the past year.
What are the analyst and broker recommendations for CTI Biopharma?
The overall consensus recommendation for CTI Biopharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the CTI Biopharma dividend yield?
CTI Biopharma does not currently pay a dividend.
Does CTI Biopharma pay a dividend?
CTI Biopharma does not currently pay a dividend.
When does CTI Biopharma next pay dividends?
CTI Biopharma does not currently pay a dividend.
How do I buy CTI Biopharma shares?
To buy shares in CTI Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CTI Biopharma?
As of the previous close price of $9.09, shares in CTI Biopharma had a market capitalisation of $1.20bn.
Where are CTI Biopharma shares listed?
Here are the trading details for CTI Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CTIC
What kind of share is CTI Biopharma?
Based on an overall assessment of its quality, value and momentum CTI Biopharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CTI Biopharma share price forecast for 2023?
The analyst consensus target price for shares in CTI Biopharma is $9.73. That is 7.04% above the last closing price of $9.09.
Analysts covering CTI Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.27 for the next financial year.
What is the trend in the CTI Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CTI Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +41.58%.
As of the last closing price of $9.09, shares in CTI Biopharma were trading +54.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CTI Biopharma PE Ratio?
The CTI Biopharma PE ratio based on its reported earnings over the past 12 months is 445.59. The shares last closed at $9.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CTI Biopharma?
CTI Biopharma's management team is headed by:
- Laurent Fischer - NEC
- Adam Craig - PRE
- David Kirske - CFO
- Bruce Seeley - COO
- Diane Parks - DRC
- Michael Metzger - NID
- David Parkinson - NID
- Matthew Perry - NID
- Reed Tuckson - NID